Dr. Peter Martin, MD

Dr. Martin practices at NYU Langone Perlmutter Cancer Center - 34th St in New York, New York.

Dr. Martin's NPI, 1952555799, was assigned on November 6, 2008. Dr. Martin graduated from University of Alberta in 2001. Dr. Martin holds New York license 252156.

Dr. Martin's primary practice is NYU Langone Perlmutter Cancer Center - 34th St, at 14 Wall St, New York, NY 10005 in New York County. The practice phone is (212) 263-1481.

Dr. Martin's primary practice is NYU Langone Perlmutter Cancer Center - 34th St in New York, New York. Dr. Martin is also affiliated with Tisch Hospital. The medical group on file is NYU Langone Orthopedic Surgery Associates. Dmand AI also links Dr. Martin to 1 more hospital, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Martin practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Martin's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Martin is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Martin's licenses on file in 2 states: New York and Florida.

Dmand AI lists chronic anemia, chronic leukemia, immune deficiency disease and lymphoma among the conditions Dr. Martin treats.

CMS data shows 835 Medicare services from Dr. Martin across 5 procedure codes in 2024, for 251 Medicare patients. Medicare paid $97,221 for them.

CMS counts 251 Medicare patients who saw Dr. Martin in 2024. The largest group is 65 to 74, with 104 patients. 75% of them have high cholesterol, and 70% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.44, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Martin's median patient age at 72, with 45% women.

In 2024, Dr. Martin wrote 106 Medicare Part D claims for 33 patients. 58% of them were for generic drugs. CMS names the drug for 61 of them, across 4 drugs with 11 or more claims each, at $429,210 in total drug cost. In 2023, CMS named 71 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Martin for performance year 2024, reported through an alternative payment model (APM). Dr. Martin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Martin as offering telehealth.

Dmand AI links 267 papers to Dr. Martin, published from 2008 to 2025. 2020 was the busiest year, with 20. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols, Lymphoma, Mantle-Cell and Rituximab. Dr. Martin has published most often in Leuk Lymphoma. Dr. Martin's most frequent co-authors are John P. Leonard, MD, Keith A. Josephs, MD and Richard R. Furman, MD.

Dmand AI links Dr. Martin to 19 clinical trials, 8 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse and Lymphoma, Non-Hodgkin. Weill Medical College of Cornell University sponsors the most, 6.

CMS Open Payments shows 125 general payments to Dr. Martin from 22 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 83% of the total. Kite Pharma, Inc. paid the most, $28,330. It also lists 16 research payments totaling $10,237 from 2016 to 2024.

Dmand AI lists 1 award for Dr. Martin, most recently CMS Stage 1 EHR in 2013.

Dr. Martin graduated from University of Alberta in 2001. Dr. Martin is a member of ASCO and ASH.

Dr. Martin is in network with 16 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.